| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ipilimumab |
| Brand | Yervoy® |
| Indication | For the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 31/05/2011 |
| Rapid review completed | 09/06/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/07/2011 |
| NCPE assessment completed | 02/09/2011 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
September 2013
The HSE has approved reimbursement following confidential price negotiations.
